Kristen Felt

TL;DR: It is shown that therapy acts on a specific subpopulation of exhausted CD8+ tumor-infiltrating lymphocytes (TILs) that retain polyfunctionality and are responsive to PD-1 blockade.

TL;DR: It is demonstrated that a strategy that uses multi-epitope, personalized neoantigen vaccination, which has previously been tested in patients with high-risk melanoma, is feasible for tumours such as glioblastoma, which typically have a relatively low mutation load and an immunologically ‘cold’ tumour microenvironment.

TL;DR: It is suggested that in NSCLC, a high number of nonsynonymous tumor mutations is associated with immune cell infiltration and inflammatory T-cell expression signatures, leading to increased sensitivity to PD-1/PD-L1 inhibition across PD-L 1 expression subgroups.

TL;DR: Insight into resistance in MSI-H tumors is provided and immunotherapeutic strategies in additional genomic contexts of colorectal cancer are suggested.

TL;DR: It is shown that anti-PD-1 therapy acts on a specific subpopulation of CD8+ tumor-infiltrating lymphocytes (TILs) in melanoma mouse models, which can also be found in patients with melanoma, and progenitor exhausted, but not terminally exhausted, CD8+.